Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy

Cancer Research

Volumn 70, Issue 9, 2010, Pages 3718-3729

  Grisendi, Giulia ^a   Bussolari, Rita ^a   Cafarelli, Luigi ^a   Petak, Istvan ^b   Rasini, Valeria ^a   Veronesi, Elena ^a   De Santis, Giorgio ^a   Spano, Carlotta ^a   Tagliazzucchi, Mara ^a   Barti Juhasz, Helga ^b   Scarabelli, Laura ^a   Bambi, Franco ^c   Frassoldati, Antonio ^a   Rossi, Giulio ^a   Casali, Christian ^a   Morandi, Uliano ^a   Horwitz, Edwin M ^d   Paolucci, Paolo ^a   Conte, Pierfranco ^a   Dominici, Massimo ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c UNIVERSITY OF FLORENCE   (Italy)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CASPASE 8; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; RETROVIRUS VECTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADIPOSE DERIVED MESENCHYMAL STEM CELL; ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER THERAPY; CELL ISOLATION; CELL KILLING; COLON CANCER; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; GENETIC CODE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CLEARANCE; MALE; MESENCHYMAL STEM CELL; MOUSE; NEOPLASM; NONHUMAN; NUCLEOTIDE SEQUENCE; PANCREAS CANCER; PLASMA HALF LIFE; PRIORITY JOURNAL; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR LOCALIZATION; UTERINE CERVIX CARCINOMA;

ADIPOCYTES; ANIMALS; APOPTOSIS; BORONIC ACIDS; CASPASE 8; CELL COMMUNICATION; COCULTURE TECHNIQUES; ENZYME ACTIVATION; FEMALE; HELA CELLS; HUMANS; MALE; MESENCHYMAL STEM CELLS; MICE; MICE, INBRED NOD; PYRAZINES; RECOMBINANT PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSDUCTION, GENETIC; UTERINE CERVICAL NEOPLASMS;

EID: 77951749301     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-1865     Document Type: Article

References (57)

1. Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ, Andreeff M. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-β delivery into tumors. Cancer Res 2002;62:3603-3608 (Pubitemid 34728832)
2. Studeny M, Marini FC, Dembinski JL, et al. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 2004;96:1593-1603 (Pubitemid 39534883)
3. Nakamura K, Ito Y, Kawano Y, et al. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther 2004;11:1155-1164 (Pubitemid 39117311)
4. Stagg J, Lejeune L, Paquin A, Galipeau J. Marrow stromal cells for interleukin-2 delivery in cancer immunotherapy. Hum Gene Ther 2004;15:597-608. (Pubitemid 41071207)
5. Khakoo AY, Pati S, Anderson SA, et al. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. Exp Med 2006;203:1235-1247 (Pubitemid 43736593)
6. Maestroni GJ, Hertens E, Galli P. Factor(s) from nonmacrophage bone marrow stromal cells inhibit Lewis lung carcinoma and B16 melanoma growth in mice. Cell Mol Life Sci 1999;55:663-667 (Pubitemid 29221598)
7. Friedenstein AJ, Deriglasova UF, Kulagina NN, et al. Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol 1974;2:83-92.
8. Zuk PA, Zhu M, Mizuno H, et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng 2001; 7:211-228 (Pubitemid 32295155)
9. Zuk PA, Zhu M, Ashjian P. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 2002;13:4279-4295 (Pubitemid 35471185)
10. Kern S, Eichler H, Stoeve J, Klüter H, Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 2006;24:1294-1301 (Pubitemid 44464698)
11. Gimble JM. Adipose tissue-derived therapeutics. Expert Opin Biol Ther 2003;3:705-713
12. Goudenege S, Pisani DF, Wdziekonski B, et al. Enhancement of myogenic and muscle repair capacities of human adipose-derived stem cells with forced expression of MyoD. Mol Ther 2009;17: 1064-1072
13. Kucerova L, Altanerova V, Matuskova M, Tyciakova S, Altaner C. Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer gene therapy. Cancer Res 2007;67:6304-6313 (Pubitemid 47037513)
14. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673-682 (Pubitemid 26091143)
15. Liabakk NB, Sundan A, Torp S, Aukrust P, Frøland SS, Espevik T. Development, characterization and use of monoclonal antibodies against sTRAIL: measurement of sTRAIL by ELISA. J Immunol Methods 2002;259:119-128 (Pubitemid 33124390)
16. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999;5:157-163 (Pubitemid 29068521)
17. Johnstone RW, Frew AJ, Smyth MJ. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 2008;8: 782-798
18. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998;281:1305-1308
19. Duiker EW, Mom CH, de Jong S, et al. The clinical trail of TRAIL. Eur J Cancer 2006;42:2233-2240
20. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104:155-162
21. Ponti D, Costa A, Zaffaroni N, et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 2005;65:5506-5511 (Pubitemid 40911148)
22. Kayagaki N, Yamaguchi N, Nakayama M, Eto H, Okumura K, Yagita H. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: a novel mechanism for the antitumor effects of type I IFNs. J Exp Med 1999;189:1451-1460 (Pubitemid 29227531)
23. Marx JC, Allay JA, Persons DA, et al. High-efficiency transduction and long-term gene expression with a murine stem cell retroviral vector encoding the green fluorescent protein in human marrow stromal cells. Hum Gene Ther 1999;10:1163-1173
24. Jo M, Kim TH, Seol DW, et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 2000;6:564-567 (Pubitemid 30305907)
25. Caltagirone S, Rossi C, Poggi A, et al. Flavonoids apigenin and quercetin inhibit melanoma growth and metastatic potential. Int J Cancer 2000;87:595-600. (Pubitemid 30639822)
26. Dominici M, Marino R, Rasini V, et al. Donor cell-derived osteopoiesis originates from a self-renewing stem cell with a limited regenerative contribution after transplantation. Blood 2008;111:4386-4391
27. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006;8:315-317
28. Wang P, Zhang J, Bellail A, et al. Inhibition of RIP and c-FLIP enhances TRAIL-induced apoptosis in pancreatic cancer cells. Cell Signal 2007;19:2237-2246 (Pubitemid 47361680)
29. Coffey JC, Wang JH, Smith MJ, et al. Phosphoinositide 3-kinase accelerates postoperative tumor growth by inhibiting apoptosis and enhancing resistance to chemotherapy-induced apoptosis. Novel role for an old enemy. J Biol Chem 2005;280:20968-20977
30. Hopkins-Donaldson S, Bodmer JL, Bourloud KB, Brognara CB, Tschopp J, Gross N. Loss of caspase-8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res 2000;60:4315-4319 (Pubitemid 32103601)
31. Brooks AD, Ramirez T, Toh U, et al. The proteasome inhibitor bortezomib (Velcade) sensitizes some human tumor cells to Apo2L/TRAIL-mediated apoptosis. Ann N Y Acad Sci 2005;1059:160-167 (Pubitemid 43211618)
32. Carter BZ, Gronda M, Wang Z. Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells. Blood 2005;105:4043-4050
33. Liu X, Yue P, Chen S, et al. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. Cancer Res 2007;67:4981-4988
34. Fry WA, Phillips JL, Menck HR. Ten-year survey of lung cancer treatments and survival in hospitals in the United States. Cancer 1999;86: 1867-1876
35. Merchant SH, Amin MB, Tamboli P, et al. Primary signet-ring cell carcinoma of lung: immunohistochemical study and comparison with non-pulmonary signet-ring cell carcinomas. Am J Surg Pathol 2001;25:1515-1519
36. Rossi G, Murer B, Cavazza A, et al. Primary mucinous (so-called colloid) carcinomas of the lung: a clinicopathologic and immunohistochemical study with special reference to CDX-2 homeobox gene and MUC2 expression. Am J Surg Pathol 2004;28:442-452
37. Leverkus M, Neumann M, Mengling T, et al. Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res 2000;60:553-559
38. Nitsch R, Bechmann I, Deisz RA, et al. Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL). Lancet 2000;356:827-828
39. Pal S, Sadhu AS, Patra S, Mukherjea KK. Histological vis-a-vis biochemical assessment on the toxic level and antineoplastic efficacy of a synthetic drug Pt-ATP on experimental animal models. J Exp Clin Cancer Res 2008;27:68.
40. Shao R, Shi Z, Gotwals PJ, Koteliansky VE, George J, Rockey DC. Cell and molecular regulation of endothelin-1 production during hepatic wound healing. Biol Cell 2003;14:2327-2341
41. Nakamizo A, Marini F, Amano T, et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 2005;65:3307-3318
42. Pereboeva L, Komarova S, Mikheeva G, Krasnykh V, Curiel DT. Approaches to utilize mesenchymal progenitor cells as cellular vehicles. Stem Cells 2003;21:389-404.
43. Duan X, Guan H, Cao Y, Kleinerman ES. Murine bone marrow-derived mesenchymal stem cells as vehicles for interleukin-12 gene delivery into Ewing sarcoma tumors. Cancer 2009;115:13-22.
44. Uchibori R, Okada T, Ito T, et al. Retroviral vector-producing mesenchymal stem cells for targeted suicide cancer gene therapy. Gene Med 2009;11:373-381
45. Kim SM, Lim JY, Park SI, et al. Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma. Cancer Res 2008;68:9614-9623
46. Sasportas LS, Kasmieh R, Wakimoto H, et al. Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci U S A 2009;106: 4822-4827
47. Loebinger MR, Eddaoudi A, Davies D, Janes SM. Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res 2009;69:4134-4142
48. Secchiero P, Melloni E, Corallini F, et al. Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells. Stem Cells 2008;26:2955-2963
49. Buchsbaum DJ, Zhou T, Lobuglio AF. TRAIL receptor-targeted therapy. Future Oncol 2006;2:493-508.
50. Takeda K, Kojima Y, Ikejima K, et al. Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease. Proc Natl Acad Sci U S A 2008;105:10895-10900
51. + cells expressing membrane-bound tumor necrosis factor-related apoptosis-inducing ligand. Hum Gene Ther 2006;17: 1225-1240
52. Mohr A, Lyons M, Deedigan L, et al. Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model. J Cell Mol Med 2008;12:2628-2643
53. Conget PA, Minguell JJ. Adenoviral-mediated gene transfer into ex vivo expanded human bone marrow mesenchymal progenitor cells. Exp Hematol 2000;28:382-390
54. Morizono K, De Ugarte DA, Zhu M, et al. Multilineage cells from adipose tissue as gene delivery vehicles. Hum Gene Ther 2003;14:59-66.
55. Seol DW, Li J, Seol MH, Park SY, Talanian RV, Billiar TR. Signaling events triggered by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): caspase-8 is required for TRAIL-induced apoptosis. Cancer Res 2001;61:1138-1143
56. Mühlenbeck F, Schneider P, Bodmer JL, et al. The tumor necrosis factor-related apoptosis-inducing ligand receptors TRAIL-R1 and TRAIL-R2 have distinct cross-linking requirements for initiation of apoptosis and are non-redundant in JNK activation. J Biol Chem 2000; 275:32208-32213
57. Zhu W, Xu W, Jiang R, et al. Mesenchymal stem cells derived from bone marrow favour tumor cell growth in vivo. Exp Mol Pathol 2006; 80:267-274